Home › Mild Cognitive Impairment › NCT05980117

Remimazolam for Cataract Surgery

Comparison of Remimazolam vs. Midazolam for Sedation During Cataract Surgery

Who can join

Ages 65 and older · All sexes

Inclusion Criteria:

1. Adult patients age \> 65 years undergoing first eye cataract surgery under local topical anesthesia at the University of California, Los Angeles (UCLA).
2. Both male and female patients
3. American Society of Anesthesiologists Class 2, 3, and 4.

Exclusion Criteria:

1. Patients who are unable to consent for the study
2. Patients who are unable to cooperate with the cognitive assessment such as patients with significant visual, auditory, language or other impairment.
3. Patients who are unable to understand simple English commands.
4. Patients who do not wish to have benzodiazepine medication during surgery
5. Patients with a history of severe hypersensitivity reaction to dextran 40 or products containing dextran 40.
6. Patients with chronic pain on opiates.
7. Patients with a history of drug, alcohol abuse/dependence.
8. Patients with BMI \> 40.
9. Patients with obstructive sleep apnea (moderate to severe).

About the study

The goal of this study is to assess any post operative cognitive changes following benzodiazepine administration during cataract surgery. The investigators will compare effects of Midazolam vs. Remimazolam on cognition at the time of discharge from the post operative care unit and the next day following surgery.

Cognitive changes will be assessed by administration of Montreal Cognitive Assessment (MoCA).

Participants will:

1. Complete MoCA testing prior to surgery 2. Randomize in either Midazolam or study drug Remimazolam 3. Complete MoCA testing after surgery at the time of discharge in the post anesthesia care unit and the next day of surgery at the time of post operative surgical visit. 4. Complete Patient Satisfaction Survey at the time of discharge from the Post Anesthesia Care Unit (PACU)

What is being tested

• Remimazolam (drug)
• Midazolam (drug)

Sponsor: University of California, Los Angeles · Participants: 120 · Started: Mar 10, 2025

Contact the study team

• Zhuang T Fang, MD · Phone: 310-267-8946
• Stephanie-Dee Sarovich, BS · Phone: 424-832-6842

Official record on ClinicalTrials.gov — NCT05980117

Locations in the U.S.

Conditions

• Mild Cognitive Impairment

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.